GENETHERA, INC. (OTCMKTS:GTHR) Files An 8-K Entry into a Material Definitive Agreement

GENETHERA, INC. (OTCMKTS:GTHR) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.

GENETHERA INC. COMPLETES THIRD MILESTONE OF THEIR “MILESTONE INVESTMENT AGREEMENT” WITH FOGT, LLC

On November 30th 2018, GeneThera Inc. completed the third milestone as described in Exhibit A of the Milestone Investment Agreement. The Completion of this milestone enables the Company to receive a payment of $1,200,000 under the Terms of the Agreement.

Item 9.01 Financial Statements and Exhibits.

GENETHERA INC Exhibit…To view the full exhibit click here
About GENETHERA, INC. (OTCMKTS:GTHR)
GeneThera, Inc. (GeneThera) is a biotechnology company. The Company focuses on improving food safety by applying the molecular technologies to eradicate cross-over (zoonotic) diseases, such as Johne’s Disease, Mad Cow Disease, Chronic Wasting Disease and E.coli. The Company focuses on developing molecular diagnostic tests, therapeutics and vaccines to help control diseases in animals and humans. GeneThera has developed diagnostic assays for use in the agricultural and veterinary markets. The Company offers specific assays for Chronic Wasting Disease among elk and deer, and Mad Cow Disease among cattle. The Company is engaged in the development of E. coli (predominantly cattle) and Johne’s disease (predominantly dairy cattle and bison) diagnostics. GeneThera’s Integrated Technology Platform (ITP) is the foundation for fast-track ribosomal DNA (rDNA) vaccine development. The Company is working on the development of a recombinant DNA vaccine for Johne’s disease.